Large-Scale Evidence-Based Guideline Development Engaging the International PCOS Community

Misso, Marie; Tassone, Eliza C.; Costello, Michael; Dokras, Anuja; Laven, Joop S.E.; Moran, Lisa; Teede, Helena

doi:10.1055/s-0038-1667312

Cited by 5 publications

(10 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Best practice evidence-based guideline development methods were applied and are detailed in the full guideline and the technical reports and outlined in Figure 1 and available at https://www.monash.edu/medicine/sphpm/mchri/pcos (11). The process aligns with all elements of the AGREEII tool for quality guideline assessment (12).…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome

Teede

Misso

Costello

et al. 2018

Fertility and Sterility

Self Cite

936

879

View full text Add to dashboard Cite

The guideline was primarily funded by the Australian National Health and Medical Research Council of Australia (NHMRC) supported by a partnership with ESHRE and the American Society for Reproductive Medicine. Guideline development group members did not receive payment. Travel expenses were covered by the sponsoring organizations. Disclosures of conflicts of interest were declared at the outset and updated throughout the guideline process, aligned with NHMRC guideline processes. Full details of conflicts declared across the guideline development groups are available at https://www.monash.edu/medicine/sphpm/mchri/pcos/guideline in the Register of disclosures of interest. Of named authors, Dr Costello has declared shares in Virtus Health and past sponsorship from Merck Serono for conference presentations. Prof. Laven declared grants from Ferring, Euroscreen and personal fees from Ferring, Euroscreen, Danone and Titus Healthcare. Prof. Norman has declared a minor shareholder interest in an IVF unit. The remaining authors have no conflicts of interest to declare. The guideline was peer reviewed by special interest groups across our partner and collaborating societies and consumer organizations, was independently assessed against AGREEII criteria and underwent methodological review. This guideline was approved by all members of the guideline development groups and was submitted for final approval by the NHMRC.

show abstract

Section: Methodsmentioning

confidence: 99%

“…GDG = guideline development group; PICO = P, patient, problem or population; I, intervention; C, comparison, control or comparator; O, outcome. Reprinted with permissions from Misso and Teede (11).…”

Section: Figurementioning

confidence: 99%

Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome

Teede

Misso

Costello

et al. 2018

Fertility and Sterility

Self Cite

936

879

View full text Add to dashboard Cite

show abstract

“…PCOS has a prevalence of 8-13% in reproductive age women (34)(35)(36) and it is one of the most common gynaecological endocrine disorders, characterized by a wide variety of symptoms. The diagnosis of PCOS is based on the presence of two out of three Rotterdam Criteria, which are oligo-anovulation, polycystic ovaries (PCO) on ultrasound and clinical and/or biochemical signs of hyperandrogenism (HA) (37), but this criteria are not always easy to apply.…”

Section: Amh As a Marker For The Diagnosis Of Pcosmentioning

confidence: 99%

“…This also reflects the controversial use of ultrasound in adolescents for the evaluation of PCO, which is closely related to AMH. In fact the new international guidelines do not recommend ultrasound evaluation in the diagnosis of PCOS until 8 years post-menarche (33)(34)(35). Therefore, AMH can be helpful in the diagnosis of PCOS together with the Rotterdam criteria, but there is a need to standardize AMH assays, improve their accuracy and to identify age specific AMH level cut-offs.…”

Section: Amh As a Marker For The Diagnosis Of Pcosmentioning

confidence: 99%

Anti-Müllerian hormone: clinical implications in Gynecological Endocrinology. An update review

et al. 2020

View full text Add to dashboard Cite

Anti-Müllerian hormone (AMH) is produced by the granulosa cells of the ovary with serum levels that grow until puberty, remain stable up to 30 years and then begin to decline until menopause. It is mainly produced by pre-and early antral follicles with an average diameter of 5-8 mm and it indirectly represents the ovarian reserve (OR). The purpose of this review is to identify what can currently be done with AMH, according to the most recent scientific evidence. AMH does not appear to be a marker for fertility as it does reflect the quantity but not the quality of follicles. It is not able to predict the spontaneous onset of pregnancy, nor the pregnancy rate in cycles of assisted reproduction technology (ART) but is a good predictor of ovarian response to hyperstimulation and it is useful in planning a couple's fertility treatment even in the case of women undergoing chemotherapy, radiotherapy and ovarian surgery. It helps to identify women suffering from mild forms of polycystic ovary syndrome (PCOS) and diagnose and manage menopause and premature ovarian failure (POF). Finally, AMH levels may be used in case of granulosa cells tumors, both for diagnosis and follow up after surgery.

show abstract

“…The guideline was rigorously developed (see Misso et al in this series) 11 integrating the best available evidence with multidisciplinary expertise and consumer preferences to provide health professionals, consumers, and policy makers with guidance on timely diagnosis, accurate assessment, and optimal treatment of PCOS, to reduce variation in care, optimize prevention of complications, and improve health outcomes.…”

Section: Polycystic Ovary Syndrome Guidelinementioning

confidence: 99%

Evaluation of a Center of Research Excellence in Polycystic Ovary Syndrome as a Large-Scale Collaborative Research Translation Initiative, Including Evaluating Translation of Guideline Impact

2018

Self Cite

View full text Add to dashboard Cite

Research translation and evaluation are often underconsidered in research design and implementation thus limiting research benefit to the end user. In this article, we first describe a best practice approach to evaluation, for a center of research excellence in polycystic ovary syndrome. Within this, we outline a comprehensive research translation program with inbuilt evaluation of the first (2018). We seek to provide a real-world example of comprehensive approaches to evaluation and research translation.

show abstract

Large-Scale Evidence-Based Guideline Development Engaging the International PCOS Community

Cited by 5 publications

References 16 publications

Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome

Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome

Anti-Müllerian hormone: clinical implications in Gynecological Endocrinology. An update review

Evaluation of a Center of Research Excellence in Polycystic Ovary Syndrome as a Large-Scale Collaborative Research Translation Initiative, Including Evaluating Translation of Guideline Impact

Contact Info

Product

Resources

About